$ACAD News

Acadia Pharmaceuticals: Why I'm Bullish Ahead Of The RADIANT Readout

BMO Capital Maintains Outperform on ACADIA Pharmaceuticals, Raises Price Target to $36

Stifel Maintains Hold on ACADIA Pharmaceuticals, Raises Price Target to $25

Acadia Pharma Secures FDA Fast Track Designation For Remlifanserin For Treatment Of Hallucinations And Delusions Associated With Alzheimer’s Disease Psychosis

RBC Capital Maintains Outperform on ACADIA Pharmaceuticals, Raises Price Target to $36

B of A Securities Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $30

Acadia Pharmaceuticals: Steady Commercial Progress, Remlifanserin Data In Focus

Citigroup Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $35

Canaccord Genuity Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $36

Acadia Pharmaceuticals Gets EMA CHMP Positive Opinion Recommending DAYBU Marketing Authorization For Rett Syndrome

Acadia Pharmaceuticals: The Song Remains The Same

A Look At ACADIA Pharmaceuticals (ACAD) Valuation After Recent Share Price Weakness

Principal Accounting Officer At ACADIA Pharmaceuticals Sells $114K Of Stock

ACADIA Pharmaceuticals Spotlights Alzheimer’s Psychosis Pipeline, NUPLAZID and DAYBUE Growth

Shareholders In ACADIA Pharmaceuticals (NASDAQ:ACAD) Should Look Beyond Earnings For The Full Story

ACADIA Pharmaceuticals Targets $1B Brand Opportunity as Key Neuropsychiatry Data Looms

ACADIA Pharmaceuticals Inc. (ACAD) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Earnings Miss: ACADIA Pharmaceuticals Inc. Missed EPS By 58% And Analysts Are Revising Their Forecasts

What ACADIA Pharmaceuticals (ACAD)'s Earnings Miss, EU Setback and R&D Transition Means For Shareholders

Citigroup Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $32